MS disease modifying treatment
Relapsing remitting multiple sclerosis (RRMS) initial therapy Very active disease: Natalizumab (Tysabri) 300 mg iv q 4 w Natalizumab: Risk of PML, 4 in 1000. check anti JC virus Ab before and at 1 year, then q 6 months or Ocrelizumab (Ocrevus): 300 mg iv, then 300 mg iv...
Tysarbi – PML
Surveillance for PML anti-JCV antibodies: at baseline and after one year PML is rare in the first year baseline brain MRI scan should be obtained prior to initiating therapy For patients who are negative for JCV antibodies at baseline and at one year, check anti-JCV antibody status and index...